메뉴 건너뛰기




Volumn 44, Issue 3, 2009, Pages 190-194

Nine-year trends in clinically relevant reduced susceptibility of HIV-1 to antiretrovirals

Author keywords

Calculated fold change; Clinical cut offs; HIV 1 resistance trends; Mutation prevalence; Phenotypic susceptibility

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; EMTRICITABINE; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

EID: 60449087073     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcv.2008.12.005     Document Type: Article
Times cited : (10)

References (22)
  • 1
    • 1442355578 scopus 로고    scopus 로고
    • HIV drug resistance
    • Clavel F., and Hance A.J. HIV drug resistance. N Engl J Med 350 (2004) 1023-1035
    • (2004) N Engl J Med , vol.350 , pp. 1023-1035
    • Clavel, F.1    Hance, A.J.2
  • 2
    • 7244234570 scopus 로고    scopus 로고
    • Current patterns in the epidemiology of primary HIV drug resistance in North America and Europe
    • Pillay D. Current patterns in the epidemiology of primary HIV drug resistance in North America and Europe. Antivir Ther 9 (2004) 695-702
    • (2004) Antivir Ther , vol.9 , pp. 695-702
    • Pillay, D.1
  • 3
    • 3142660152 scopus 로고    scopus 로고
    • The prevalence of antiretroviral drug resistance in the United States
    • Richman D.D., Morton S.C., Wrin T.F., Hellman N., Berry S., Shapiro S.F., et al. The prevalence of antiretroviral drug resistance in the United States. AIDS 18 (2004) 1393-1401
    • (2004) AIDS , vol.18 , pp. 1393-1401
    • Richman, D.D.1    Morton, S.C.2    Wrin, T.F.3    Hellman, N.4    Berry, S.5    Shapiro, S.F.6
  • 5
    • 33846025131 scopus 로고    scopus 로고
    • Epidemiology of antiretroviral drug resistance in drug-naïve persons
    • Geretti A.M. Epidemiology of antiretroviral drug resistance in drug-naïve persons. Curr Opin Infect Dis 20 (2007) 22-32
    • (2007) Curr Opin Infect Dis , vol.20 , pp. 22-32
    • Geretti, A.M.1
  • 6
    • 41449090659 scopus 로고    scopus 로고
    • SPREAD programme: transmission of drug-resistant HIV-1 in Europe remains limited to single classes
    • Wensing A.M.J., Vercauteren J., van de Vijver D.A., Albert J., Asjo B., Balotta C., et al. SPREAD programme: transmission of drug-resistant HIV-1 in Europe remains limited to single classes. AIDS 22 (2008) 625-635
    • (2008) AIDS , vol.22 , pp. 625-635
    • Wensing, A.M.J.1    Vercauteren, J.2    van de Vijver, D.A.3    Albert, J.4    Asjo, B.5    Balotta, C.6
  • 7
    • 42149172733 scopus 로고    scopus 로고
    • Prevalence, genotypic associations and phenotypic characterization of K65R, L74V and other HIV-1 RT resistance mutations in a commercial database
    • McColl D.J., Chappey C., Parkin N.T., and Miller M.D. Prevalence, genotypic associations and phenotypic characterization of K65R, L74V and other HIV-1 RT resistance mutations in a commercial database. Antivir Ther 13 (2008) 189-197
    • (2008) Antivir Ther , vol.13 , pp. 189-197
    • McColl, D.J.1    Chappey, C.2    Parkin, N.T.3    Miller, M.D.4
  • 8
    • 33646769915 scopus 로고    scopus 로고
    • Interpreting resistance data for HIV-1 therapy management-know the limitations
    • Van Laethem K., and Vandamme A.M. Interpreting resistance data for HIV-1 therapy management-know the limitations. AIDS Rev 8 (2006) 37-43
    • (2006) AIDS Rev , vol.8 , pp. 37-43
    • Van Laethem, K.1    Vandamme, A.M.2
  • 9
    • 0344474694 scopus 로고    scopus 로고
    • A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs
    • Hertogs K., de Béthune M.-P., Miller V., Ivens T., Schel P., Van Cauwenberge A., et al. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob Agents Chemother 42 (1998) 269-276
    • (1998) Antimicrob Agents Chemother , vol.42 , pp. 269-276
    • Hertogs, K.1    de Béthune, M.-P.2    Miller, V.3    Ivens, T.4    Schel, P.5    Van Cauwenberge, A.6
  • 11
    • 34547841291 scopus 로고    scopus 로고
    • Prediction of HIV-1 drug susceptibility phenotype from the viral genotype using linear regression modeling
    • Vermeiren H., Van Craenenbroeck E., Alen P., Bacheler L., Picchio G., Lecocq P., et al. Prediction of HIV-1 drug susceptibility phenotype from the viral genotype using linear regression modeling. J Virol Methods 145 (2007) 47-55
    • (2007) J Virol Methods , vol.145 , pp. 47-55
    • Vermeiren, H.1    Van Craenenbroeck, E.2    Alen, P.3    Bacheler, L.4    Picchio, G.5    Lecocq, P.6
  • 12
    • 42649118796 scopus 로고    scopus 로고
    • Determination of clinically relevant cut-offs for HIV-1 phenotypic resistance estimates through a combined analysis of clinical trial and cohort data
    • Winters B.W., Montaner J., Harrigan P.R., Gazzard B., Pozniak A., Miller M.D., et al. Determination of clinically relevant cut-offs for HIV-1 phenotypic resistance estimates through a combined analysis of clinical trial and cohort data. J Acquir Immune Defic Syndr 48 (2007) 26-34
    • (2007) J Acquir Immune Defic Syndr , vol.48 , pp. 26-34
    • Winters, B.W.1    Montaner, J.2    Harrigan, P.R.3    Gazzard, B.4    Pozniak, A.5    Miller, M.D.6
  • 13
    • 33845943963 scopus 로고    scopus 로고
    • HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance
    • Shafer R.W., Rhee S.Y., Pillay D., Miller V., Sandstrom P., Schapiro J.M., et al. HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance. AIDS 21 (2007) 215-223
    • (2007) AIDS , vol.21 , pp. 215-223
    • Shafer, R.W.1    Rhee, S.Y.2    Pillay, D.3    Miller, V.4    Sandstrom, P.5    Schapiro, J.M.6
  • 14
    • 60449096553 scopus 로고    scopus 로고
    • Los Alamos National Laboratory Database, Los Alamos, NM, USA
    • Los Alamos National Laboratory Database, Los Alamos, NM, USA. www.hiv.lanl.gov.
  • 15
    • 84887667223 scopus 로고    scopus 로고
    • The French ANRS National Agency for AIDS Research
    • The French ANRS (National Agency for AIDS Research): HIV French Resistance http://www.hivfrenchresistance.org/2008/tab1.html.
    • Resistance
    • French, H.I.V.1
  • 16
    • 60449090686 scopus 로고    scopus 로고
    • Stanford University HIV Drug Resistance Database
    • Stanford University HIV Drug Resistance Database. http://hivdb.stanford.edu/index.html.
  • 17
    • 60449095062 scopus 로고    scopus 로고
    • US Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents-A Working Group of the Office of AIDS Research Advisory Council OARAC, Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents January 2008. AIDS info web site
    • US Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents-A Working Group of the Office of AIDS Research Advisory Council (OARAC). Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents January 2008. AIDS info web site: http://AIDSinfo.nih.gov.
  • 18
    • 60449100323 scopus 로고    scopus 로고
    • Guidelines for the clinical management and treatment of HIV-infected adults in Europe/Version 2, December 2007 at the EACS web site: http://www.eacs.eu/guide/index.htm.
    • Guidelines for the clinical management and treatment of HIV-infected adults in Europe/Version 2, December 2007 at the EACS web site: http://www.eacs.eu/guide/index.htm.
  • 19
    • 41349117196 scopus 로고    scopus 로고
    • Efficacy and safety of once-daily regimens in the treatment of HIV infection
    • Molina J.-M. Efficacy and safety of once-daily regimens in the treatment of HIV infection. Drugs 68 (2008) 567-578
    • (2008) Drugs , vol.68 , pp. 567-578
    • Molina, J.-M.1
  • 20
    • 14744283486 scopus 로고    scopus 로고
    • Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlates
    • Mo H., King M.S., King K., Molla A., Brun S., and Kempf D. Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlates. J Virol 79 (2005) 3329-3338
    • (2005) J Virol , vol.79 , pp. 3329-3338
    • Mo, H.1    King, M.S.2    King, K.3    Molla, A.4    Brun, S.5    Kempf, D.6
  • 21
    • 0038369071 scopus 로고    scopus 로고
    • HIV-1 reverse transcriptase and protease resistance mutations selected during 16-72 weeks of therapy in isolates from antiretroviral therapy-experienced patients receiving abacavir/efavirenz/amprenavir in the CNA2007 study
    • Ait-Khaled M., Rakik A., Griffin P., Stone C., Richards N., Thomas D., Falloon J., and Tisdale M. HIV-1 reverse transcriptase and protease resistance mutations selected during 16-72 weeks of therapy in isolates from antiretroviral therapy-experienced patients receiving abacavir/efavirenz/amprenavir in the CNA2007 study. Antivir Ther 8 (2003) 111-120
    • (2003) Antivir Ther , vol.8 , pp. 111-120
    • Ait-Khaled, M.1    Rakik, A.2    Griffin, P.3    Stone, C.4    Richards, N.5    Thomas, D.6    Falloon, J.7    Tisdale, M.8
  • 22
    • 2442657656 scopus 로고    scopus 로고
    • Identification of I50L as the signature atazanavir (ATV)-resistance mutation in treatment-naïve HIV-1-infected patients receiving ATV-containing regimens
    • Colonno R., Rose R., Mclaren C., Thiry A., Parkin N., and Friborg J. Identification of I50L as the signature atazanavir (ATV)-resistance mutation in treatment-naïve HIV-1-infected patients receiving ATV-containing regimens. J Infect Dis 189 (2004) 1802-1810
    • (2004) J Infect Dis , vol.189 , pp. 1802-1810
    • Colonno, R.1    Rose, R.2    Mclaren, C.3    Thiry, A.4    Parkin, N.5    Friborg, J.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.